We scan new podcasts and send you the top 5 insights daily.
Edward van Vaesel says Merck/MSD was reorganizing and firing local staff, which made it willing to discuss out-licensing a shelved compound. Asserta secured rights to a preclinical asset that the big pharma had overlooked. That access was the starting point for the company and a very useful one.
Edward van Vaesel describes Asserta's lead compound as a shelved Merck/MSD asset that came with prior pharma safety and pharmacology data. He says that scrutiny and existing data helped at the start, even though the molecule had never been tested in a leukemia model initially.
K-36's lead drug was acquired from Novartis not because it was a failed asset, but because it became available during a strategic reorganization. This illustrates a key opportunity for biotech startups: licensing promising preclinical assets that no longer fit a large pharmaceutical company's immediate development focus.
Roivant's early success came from identifying and building companies around promising drug assets that were deemed non-strategic by large pharmaceutical firms. This approach capitalized on undervalued IP and focused execution, pre-dating the now-common trend of pharma spin-outs.
To prepare for its internally discovered drugs, Eikon Therapeutics first in-licensed external programs. This allowed their newly-formed clinical team, led by a Merck veteran, to build cohesion and processes on existing assets, avoiding the risk of testing their teamwork for the first time on novel, internally-developed molecules.
Discontinued drugs aren't hard to identify; the real challenge is navigating the out-licensing process inside a large pharma company. Without an internal champion to drive the complex approvals for a non-priority asset, promising drugs can languish on the shelf due to corporate inertia, not a desire to hide them.
As large pharmaceutical companies shift focus to acquiring clinically validated assets, a gap has emerged in early-stage development. Smaller and mid-sized pharmas, unable to compete on price for late-stage assets, are now incentivized to take on more risk and partner earlier, driving innovation.
BGV's massive success, Assertifarma, originated from a Merck reorganization. The founding team, who were being let go, identified a shelved drug intended for inflammation and repurposed it for leukemia, negotiating the license amidst the corporate shuffle. This highlights the hidden opportunities within large pharma portfolios.
Lyora Therapeutics' model is built on acquiring promising, pre-clinically validated programs that larger companies shelved due to strategic shifts. This "asset-driven" approach allows a new company to rapidly build a pipeline without the cost and time of early-stage discovery, capitalizing on the sunk R&D costs of former owners.
A key organizational flaw prevents valuable shelved assets from being repurposed. In large pharma, actively managing and out-licensing these candidates is not a defined role. Business development is incentivized to in-license new assets, while R&D leaders focus on the active pipeline. This structural gap leaves valuable drugs in corporate limbo.
Large pharma companies increasingly rely on smaller biotechs for early-stage, high-risk innovation. Startups operate with higher risk tolerance and faster decision-making. Once a drug shows promise, the larger company, with its vast resources and expertise in running large-scale trials, steps in to license or acquire it for scaling.